UMB Bank n.a. Sells 334 Shares of Novo Nordisk A/S (NYSE:NVO)

UMB Bank n.a. reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,430 shares of the company’s stock after selling 334 shares during the period. UMB Bank n.a.’s holdings in Novo Nordisk A/S were worth $3,564,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hsbc Holdings PLC lifted its stake in shares of Novo Nordisk A/S by 19.4% during the 2nd quarter. Hsbc Holdings PLC now owns 54,804 shares of the company’s stock valued at $7,852,000 after buying an additional 8,922 shares in the last quarter. AE Wealth Management LLC lifted its position in shares of Novo Nordisk A/S by 161.5% in the second quarter. AE Wealth Management LLC now owns 19,319 shares of the company’s stock valued at $2,758,000 after acquiring an additional 11,930 shares in the last quarter. Epoch Investment Partners Inc. grew its position in shares of Novo Nordisk A/S by 4.5% during the second quarter. Epoch Investment Partners Inc. now owns 14,132 shares of the company’s stock worth $2,017,000 after purchasing an additional 614 shares in the last quarter. Gabelli Funds LLC raised its stake in Novo Nordisk A/S by 35.7% during the 2nd quarter. Gabelli Funds LLC now owns 46,963 shares of the company’s stock valued at $6,703,000 after purchasing an additional 12,363 shares during the period. Finally, DRW Securities LLC purchased a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $1,298,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on NVO. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Trading Down 5.2 %

Shares of NYSE NVO opened at $78.74 on Tuesday. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The business’s 50 day moving average is $97.76 and its two-hundred day moving average is $116.89. The stock has a market capitalization of $353.33 billion, a P/E ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.